Year: 2023

TORONTO, CANADA — (September 8, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. … Continued

– Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study – PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 –  Ended quarter with $34.3 million in cash and equivalents TORONTO, CANADA — (August 14, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen … Continued

– Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway – PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 –  Ended year with $38.9 million in cash and equivalents  TORONTO, CANADA — (June 29, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its … Continued

TORONTO, CANADA — (April 25, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 – 2, 2023. Dr. Joseph Stauffer, Antibe’s … Continued

TORONTO, CANADA — (April 18, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in person on April 25-26, 2023. Scott Curtis, Antibe’s … Continued

TORONTO, CANADA — (April 11, 2023) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formulation Further to Antibe’s update of February 15, 2023, the … Continued

– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management – Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months – Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (February 15, … Continued